enGene Therapeutics (ENGN) Other financing activities (2023 - 2026)

enGene Therapeutics (ENGN) has 4 years of Other financing activities data on file, last reported at -$103.0 million in Q2 2026.

• For the quarter ending Q2 2026, Other financing activities fell 51858.79% year-over-year to -$103.0 million; the trailing twelve-month figure through Jul 2026 stood at $25.2 million (down 58.2% YoY), and the FY2025 full-year result was $2.2 million, down 99.15% from the prior year.
• Other financing activities was -$103.0 million for Q2 2026 at enGene Therapeutics, down from $126.2 million in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $126.2 million in Q1 2026 to a low of -$103.0 million in Q2 2026.
• A 4-year average of $17.8 million and a median of $1.1 million in 2025 frame the typical range for Other financing activities.
• The largest YoY upside for Other financing activities was 12624900.0% in 2026 against a maximum downside of 51858.79% in 2026.
• enGene Therapeutics' Other financing activities stood at $56.9 million in 2023, then grew by 5.76% to $60.1 million in 2024, then sank by 96.69% to $2.0 million in 2025, then tumbled by 5273.28% to -$103.0 million in 2026.
• Per Business Quant data, the three most recent Other financing activities figures were -$103.0 million in Q2 2026, $126.2 million in Q1 2026, and $2.0 million in Q4 2025.